Hydrogen water research achieves better results
2020-11-10
The latest research from Qian Liren's research group from the Department of Hematology, the Sixth Medical Center of the PLA General Hospital, proves that drinking hydrogen water (4 ml/kg body weight) 3 times a day can effectively treat cGVHD
Chronic graft versus host disease (cGVHD) is the main cause of non-transplant death after allogeneic hematopoietic stem cell transplantation. At present, the first-line treatment is glucocorticoids, but there is no standard treatment for patients who are refractory or dependent on corticosteroid therapy. Considering that a large number of studies have shown that hydrogen has an anti-inflammatory effect, has a certain preventive effect on rejection after organ transplantation, and the side effects of hydrogen are small, the researchers speculate that hydrogen may have a therapeutic effect on patients with cGVHD.
To prove this speculation, the researchers conducted a prospective open phase 2 hydrogen medicine study. The patient took 4ml/kg hydrogen-rich water orally three times a day. The reactions of the skin, mouth, gastrointestinal (GI), liver, eyes, lungs, joints and fascia are graded every 3 months. A total of 24 patients (median age 27 years) were included in the study. Of the 24 patients, 18 (75%; 95% CI, 55.1% to 88%) had an objective response. No obvious toxicity was observed in all subjects. The estimated 4-year overall survival rate was 74.7% (95% CI, 54.9%-94.5%). The survival time of the response group was significantly prolonged. The 4-year survival rate of the response group was significantly higher than that of the non-response group (86.6% vs 0%; p= 0.000132). Hydrogen not only has a significant effect on cGVHD patients, but also has no obvious side effects from long-term use of hydrogen.
